I'm LongbridgeAI, I can summarize articles.NovaBridge Biosciences appointed Srishti Gupta, MD MPP, as CEO effective July 1, 2026, replacing outgoing CEO Sean Fu. Gupta joins the board and will focus on advancing givastomig, expanding the Visara ophthalmology franchise, and pursuing partnerships. Fu steps down to pursue other opportunities but remains in an advisory role during the transition.
- NovaBridge Biosciences named Srishti Gupta, MD MPP as CEO effective July 1, 2026. * Gupta also joins the board; she brings more than two decades of leadership in biopharmaceuticals, global health, strategy. * Outgoing CEO Xi-Yong (Sean) Fu will step down to pursue other opportunities. * Fu will remain in an advisory role during the transition. * Gupta will prioritize advancing givastomig toward registration, expanding the Visara ophthalmology franchise, pursuing strategic partnerships. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-286812), on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here